Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3779 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Trigen obtains license to GPVI Technology

Under the agreement Millennium will receive upfront payments, payments for development and regulatory milestones, and sales royalties on future products. Specific financial details were not disclosed. GPVI is

Shire licenses HIV compound to Avexa

The rights have been licensed in return for an up-front payment of $10 million, development and sales related milestones and royalties. Shire will also receive 8 million additional

Coley suspends hepatitis drug, cuts jobs

Employees affected by the reduction have been offered severance and outplacement support. The estimated termination charges will be approximately $1.1 million. Suspending the development of Actilon is expected

Nutrition 21 yeast product suppresses HIV

These findings are significant because boosting the immune system’s CD4 cell count and suppressing viral loads can decrease the likelihood of developing complication of HIV disease and prolong

Blood pressure drug may treat muscular dystrophy

Genetically engineered mice with Marfan syndrome were given losartan, a hypertension drug. The drug was found to dramatically strengthen the aorta, the major artery carrying blood away from